Clinical trials: Platelet Reactivity, open to volunteers
Coronary Artery Disease, Percutaneous Coronary Intervention
Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty.
Patients who undergo percutaneous coronary intervention (PCI) are commonly treated with antiplatelet therapy to prevent stent thrombosis and recurrence of events.
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndromes, Antiplatelet Therapy
- Trial name
- HI-TECH 2 (NCT07582835)
- Testing
- Clopidogrel, Ticagrelor, Prasugrel
- Where
- Switzerland
- Volunteers
- 355 people
- Sponsor
- Cardiocentro Ticino
Cardiovascular Prevention
A Pilot Study to Investigate Platelet Reactivity in Patients With Elevated Lipoprotein(a) and Its Response to Antiplatelet Therapy
The Lp(a)-PLAT Study is designed to close a critical evidence gap in cardiovascular prevention for the roughly 20% of the population who carry genetically determined elevations in lipoprotein(a) - a recognised pro-thrombotic and…
- Trial name
- Lp(a)-PLAT (NCT07720934)
- Testing
- Aspirin, Clopidogrel
- Where
- Switzerland
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- François MACH
Coronary Artery Disease
A Precision Medicine Approach to Identify Patients Undergoing Elective PCI at Risk of Peri-PCI Myocardial Infarction
Despite the relative safety of PCI with new generation stents, peri-PCI thrombotic complications, including myocardial infarction and myocardial injury, are common in elective PCI, occurring in up to 30% of patients.
- Trial name
- NCT05332262
- Testing
- Assessment of platelet reactivity, Troponin measurement
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- University of Florida
Coronary Artery Disease
Tailored Anti-platelet Therapy After DES Implantation in High-risk Patients
Clopidogrel monotherapy has been found effective in reducing ischaemic cardiovascular and haemorrhagic complications in patients with drug-eluting stent (DES) placement.
- Trial name
- NCT05936606
- Testing
- Clopidogrel monotherapy, Tailored anti-platelet therapy
- Where
- South Korea
- Volunteers
- 3,434 people
- Sponsor
- Yonsei University
Arteriosclerosis, Acute Myocardial Infarction
Menopause Related Influences on Leukocyte Distribution, Monocyte Function and Platelet Reactivity
Women and men show marked differences in cardiovascular risk profile and outcome. Women experience fewer cardiovascular events than men before menopause, but this relationship seems to reverse at menopause.
- Conditions
- Arteriosclerosis, Acute Myocardial Infarction, Cardiovascular Events, Menopause
- Trial name
- NCT05985447
- Where
- Germany
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Heinrich-Heine University, Duesseldorf
Erythropoietin Adverse Reaction
The Effect of Salicylate on Platelet Function in CKD (Chronic Kidney Disease) Patients Treated With Aranesp
The aim of the study is to 1. To determine whether treatment with Erythropoiesis-stimulating agents (in the form of Aranesp®) affects platelet function, and how. 2.
- Trial name
- EPOASA (NCT04330729)
- Testing
- Acetylsalicylic acid
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- Zealand University Hospital
Peripheral Arterial Disease (PAD), Amputation
Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease
The goal of this clinical trial is to determine whether a personalised blood clot prevention plan is more effective than standard treatment in adults with peripheral artery disease (PAD) who have undergone a procedure to restore…
- Conditions
- Peripheral Arterial Disease (PAD), Amputation, Thrombosis, Thrombosis (Stent Thrombosis)
- Trial name
- NCT07613840
- Testing
- Aspirin, Clopidogrel, Ticagrelor
- Where
- 2 sites in United States
- Volunteers
- 484 people
- Sponsor
- Massachusetts General Hospital
Coronary Arterial Disease (CAD), ACS (Acute Coronary Syndrome)
Impact of CYP2C19 Genotype-guided Approach in Antiplatelet Therapy on Platelet Reactivity Index Among Coronary Artery Disease (CAD) Patients
The goal of this clinical trial is to learn if the pilot intervention of CYP2C19 genotype-guided antiplatelet therapy works to reduce the occurrence of cardiovascular events after Percutaneous Coronary Intervention (PCI) done in…
- Conditions
- Coronary Arterial Disease (CAD), ACS (Acute Coronary Syndrome), SCAD
- Trial name
- NCT06759272
- Testing
- CYP2C19 genotype-guided antiplatelet therapy
- Where
- Malaysia
- Volunteers
- 120 people
- Sponsor
- Nur Hafizah Annezah binti Utuh
ACS - Acute Coronary Syndrome, Ticagrelor
Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor
The FLORA-ACS study aims to evaluate the relationship between dysbiosis and high platelet reactivity during treatment with ticagrelor in patients with a history of acute coronary syndromes and investigate the use of rifaximin to…
- Conditions
- ACS - Acute Coronary Syndrome, Ticagrelor, Microbiota, Platelet Aggregation
- Trial name
- FLORA-ACS (NCT07203846)
- Testing
- Rifaximin
- Where
- Poland
- Volunteers
- 50 people
- Sponsor
- Collegium Medicum w Bydgoszczy
Healthy Volunteers, Erythritol
SUVY VerSus SAccharose (SUVISA)
Sugar substitutes are increasingly used to reduce sugar intake. SÜVY is a food ingredient combining erythritol and polydextrose.
- Trial name
- SUVISA (NCT07901491)
- Testing
- SÜVY, Sucrose
- Where
- France
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Minerais SAS
Chronic Coronary Syndrome
Effect of ZaStaprazan on Platelet Reactivity of Clopidogrel After PercuTaneous CoronAry InteRvention
The purpose of this study is to evaluate the clinical utility of zastaprazan compared to proton pump inhibitors (PPIs) in patients receiving dual antiplatelet therapy (DAPT) including clopidogrel after percutaneous coronary…
- Trial name
- EZ-STAR (NCT07471867)
- Testing
- Zastaprazan, Rabeprazole
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Yonsei University
Coronary Artery Disease
Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention
The proposed study aims to assess the antiplatelet effects of more potent oral P2Y12 inhibition with low-dose ticagrelor (60 mg bid) compared with standard of care clopidogrel in patients with a high ABCD-GENE score (≥10).
- Trial name
- NCT06228456
- Testing
- Ticagrelor 60mg, Clopidogrel
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Florida